Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: Mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function

Psychopharmacology

Volumn 231, Issue 5, 2014, Pages 875-888

  Eshleman, Amy J ^a,b   Forster, Michael J ^c   Wolfrum, Katherine M ^a   Johnson, Robert A ^a   Janowsky, Aaron ^a,b,d   Gatch, Michael B ^c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

( ) 2,5 dimethoxy 4 methylamphetamine; Drug abuse; Drug discrimination; Locomotor activity; Lysergic acid diethylamide (LSD); Serotonin receptor; Substituted phenethylamines

Indexed keywords

2,5 DIMETHOXY 4 CHLOROAMPHETAMINE; 2,5 DIMETHOXY 4 CHLOROPHENETHYLAMINE; 2,5 DIMETHOXY 4 ETHYLPHENETHYLAMINE; 2,5 DIMETHOXY 4 ETHYLTHIOPHENETHYLAMINE; 2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 2,5 DIMETHOXY 4 METHYLPHENETHYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; LYSERGIDE; METHAMPHETAMINE; N,N DIMETHYLTRYPTAMINE; NORADRENALIN TRANSPORTER; PHENETHYLAMINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; SEROTONIN RECEPTOR; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG DISCRIMINATION TEST; HUMAN; HUMAN CELL; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; NORADRENALIN RELEASE; NORADRENALIN UPTAKE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONIN UPTAKE; ANIMAL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; MOUSE; PERCEPTIVE DISCRIMINATION; SPRAGUE DAWLEY RAT;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; N,N-DIMETHYLTRYPTAMINE; PHENETHYLAMINES; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84896733364     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3303-6     Document Type: Article

References (51)

1. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP (2002) Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol 136:510-519
2. Backstrom JR, Chang MS, Chu H, Niswender CM, Sanders-Bush E (1999) Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology 21:77S-81S
3. Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol 6:263-275
4. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104
5. Bosak A, Lovecchio F, Levine M (2013) Recurrent seizures and serotonin syndrome following 2C-I ingestion. J Med Toxicol 9(2):196-198
6. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
7. Cohen S (1967) Psychotomimetic agents. Annu Rev Pharmacol 7:301-318
8. de Boer D, Bosman I (2004) A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm World Sci 26:110-113
9. DEA (2013) DEA Title 21 Code of federal regulations, Section 1308.11 Schedule 1(d) hallucinogenic substances. http://www.deadiversion.usdoj.gov/ 21cfr/cfr/1308/1308-11.htm. Accessed 3 Sept 2013
10. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9:172-178
11. Drees JC, Stone JA, Wu AH (2009) Morbidity involving the hallucinogenic designer amines MDA and 2C-I. J Forensic Sci 54:1485-1487
12. Egan C, Grinde E, DuPre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000) Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35:144-150
13. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877-885
14. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85:1803-1815
15. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH (2005) Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 181:496-503
16. Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33
17. Fiorella D, Rabin RA, Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: antagonist correlation analysis. Psychopharmacology (Berl) 121:347-356
18. Gatch MB, Rutledge MA, Carbonaro T, Forster MJ (2009) Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology (Berl) 204:715-724
19. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ (2011) Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther 338:280-289
20. Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511
21. Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61:364-381
22. 125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav 35:211-217
23. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370:114-123
24. Krebs KM, Geyer MA (1994) Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology (Berl) 113:429-437
25. Krebs-Thomson K, Paulus MP, Geyer MA (1998) Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339-351
26. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237
27. Li JX, Koek W, Rice KC, France CP (2010) Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys. J Pharmacol Exp Ther 333:244-252
28. McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem 49:5794-5803
29. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321:1054-1061
30. Nagai F, Nonaka R, Satoh Hisashi KK (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137
31. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. The National Academies Press, Washington, DC
32. 35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256
33. Nichols DE (1986a) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313
34. Nichols DE (1986b) Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol Biochem Behav 24:335-340
35. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181
36. Nonaka R, Nagai F, Ogata A, Satoh K (2007) In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes. Biol Pharm Bull 30:2328-2333
37. Oberlender R, Nichols DE (1988) Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl) 95:71-76
38. Ovaska H, Viljoen A, Puchnarewicz M, Button J, Ramsey J, Holt DW, Dargan PI, Wood DM (2008) First case report of recreational use of 2,5-dimethoxy-4- chloroamphetamine confirmed by toxicological screening. Eur J Emerg Med 15:354-356
39. Parrish JC, Braden MR, Gundy E, Nichols DE (2005) Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. J Neurochem 95:1575-1584
40. Rabin RA, Regina M, Doat M, Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72:29-37
41. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, Grewal JS, Garnovskaya MN (2001) Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 92:179-212
42. Sacks J, Ray MJ, Williams S, Opatowsky MJ (2012) Fatal toxic leukoencephalopathy secondary to overdose of a new psychoactive designer drug 2C-E (Europa). Proc (Bayl Univ Med Cent) 25:374-376
43. Sanders-Bush E, Burris KD, Knoth K (1988) Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 246:924-928
44. Schechter MD (1998) MDMA-like stimulus effects of hallucinogens in male Fawn-Hooded rats. Pharmacol Biochem Behav 59:265-270
45. Schindler EA, Harvey JA, Aloyo VJ (2013) Phospholipase C mediates (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex. Brain Res 1491:98-108
46. Shulgin AT, Shulgin A (1991) Pihkal: a chemical love story. Transform, Berkeley, CA
47. Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94:213-216
48. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466
49. Van Vrancken MJ, Benavides R, Wians FH Jr (2013) Identification of designer drug 2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose. Proc (Bayl Univ Med Cent) 26:58-61
50. Villalobos CA, Bull P, Saez P, Cassels BK, Huidobro-Toro JP (2004) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br J Pharmacol 141:1167-1174
51. Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) 203:251-263